マイクロバイオーム (微生物叢) の現状
The State of the Microbiome
|出版日||ページ情報||英文 39 Pages
|マイクロバイオーム (微生物叢) の現状 The State of the Microbiome|
|出版日: 2019年01月31日||ページ情報: 英文 39 Pages||
当レポートでは、世界のマイクロバイオーム (微生物叢) 市場について調査分析し、マイクロバイオームの投資、関連の課題、治療薬の開発・開始・製造について、体系的な情報を提供しています。
Investment in Microbiome therapeutics is low across all therapy areas, but the infectious disease and gastrointestinal spaces are bringing in the highest levels of investment at 2.7 on a five-point scale. Identifying the mechanism of action was indicated by 27% of respondents as the most challenging aspect of developing Microbiome therapeutics. Also it is anticipated that the regulatory bodies may require drug developers to demonstrate the mechanisms of action of Microbiome therapeutics in order to gain regulatory approval.
Microbiome therapeutics was defined to include both live biotherapeutic products and products targeting the microbiome, excluding over the counter probiotics. As indicated, drug developers will face the challenge of manufacturing microbiome therapeutics using a cost-effective and scalable process that is consistent from batch to batch. Respondents indicated manufacturing (including consistency of strain) will be the most challenging aspect of launching microbiome therapeutics.
The report "The State of the Microbiome", provides an assessment of how the pharmaceutical industry perceives the state of the Microbiome, including the challenges associated with developing, launching, and manufacturing Microbiome therapeutics as well as where opportunity remains to invest in the Microbiome space.
The report is built on analyst expertise on the results of a 10 minutes survey of 158 Pharmaceuticals participants which was fielded from December 20, 2018 to January 7, 2019. Participants answered questions about the challenges they anticipate to impact the development, launch, manufacturing of Microbiome therapeutics.